Claudia Zeri

T: +31 70 376 06 21
E: claudia.zeri@barentskrans.nl
View Claudia Zeri on LinkedIn

Claudia Zeri works in the practice group IP & Technology, where she practices all fields of Intellectual Property rights. She has experience in advising and litigating in relation to patents in several technical fields, including the telecommunications sector, the field of mechanical engineering, the pharmaceutical and the biotechnological sector. She also advises in and litigates before the national and EU courts in cases relating to trademark and design law (among which consumer articles and household appliances). Furthermore, Claudia advises clients in the pharmaceutical sector on national and European level with respect to regulatory proceedings relating to medicinal products.

Professional activities

Board Member of the Licensing Executives Society Benelux (LES Benelux)
Member of the Association Internationale des Jeunes Avocats (AIJA)
Member of the Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI)
Member of the European Patent Lawyers Association (EPLAW)
Member of the International Trademark Association (INTA)
Member of Vereniging Intellectuele Eigendom Proces Advocaten (VIEPA)

News and publications

Confidential Information in Dutch IP Proceedings: From “Don’t Ask, Don’t Tell” to “Show and Tell”

Claudia Zeri, senior associate in the practice group IP & Technology, recently co-authored an article on presenting, obtaining and protecting Confidential Information in Dutch IP Proceedings for EIPR. In the article, the improved possibilities to obtain information and protecting such, is explained. Introduction ‘The article discusses the possibilities for protecting confidential information on the one
Read more ›

Pharma update: pemetrexed tromethamine does not infringe pemetrexed disodium patent

In its judgment of 19 June 2019, the District Court of The Hague ruled that Fresenius Kabi’s pemetrexed tromethamine falls outside the scope of protection of Eli Lilly’s patent for pemetrexed disodium. This final relief decision deviates from earlier decisions in interim relief proceedings and decisions by several foreign courts. Eli Lilly (“Lilly”) markets the
Read more ›
More from this specialist